Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06928272 · ClinicalTrials.gov registry record · Phase 3
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
A Phase 3 study of Long COVID, sponsored by Douglas D. Fraser.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
- 8
- Study locations
NCT06928272: Recruiting Phase 3 study of Long COVID, sponsored by Douglas D. Fraser.
NCT06928272 is a Phase 3 study of Long COVID that is actively recruiting participants, run by Douglas D. Fraser. The registered enrollment target is 348 participants, below the 2,181-participant average among 50 other Long COVID trials with a reported enrollment target (84% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06928272, a Phase 3 study of Long COVID, is actively recruiting participants, sponsored by Douglas D. Fraser.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
- 8
- Study locations
Study Summary
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.
Primary Outcome
The aim of this study is to evaluate the efficacy of two repurposed drugs in reducing symptom severity in participants with Long Covid. The change in symptom score (transformed scale of 0-100) from baseline to both the interim and final analyses will be compared across one of the five validated subscales, relative to the placebo. This study will utilize five validated subscales: 1) Fatigue, 2) Breathing, 3) Memory, Thinking, and Communication, 4) Muscles and Joints, and 5) Circulation. Each sub
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Pirfenidone
- DRUG Placebo for pirfenidone
- DRUG Placebo for upadacitinib
Study Locations (8)
Quebec
- Institut de Recherches Cliniques de Montréal (IRCM) - Montreal
- Centre de Recherche du CHUS (CRCHUS) - Sherbrooke
Roma
- INMI Lazzaro Spallanzani IRCCS - Roma
- Sapienza Università di Roma - Roma
California
- Laura Rodriguez Research Institute - San Diego
Rio de Janerio
- Ini-Fiocruz - Rio de Janeiro
Kampala
- Joint Clinical Research Centre (JCRC) - Kampala
Lusaka Province
- University Teaching Hospital - Lusaka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT06928272 shows while recruiting
NCT06928272 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 2,181-participant average among 50 other Long COVID trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Long COVID appearing as the primary indexed condition, and to 4 interventions - of which Upadacitinib is the first listed.
NCT06928272 lists 8 locations in 6 states (Quebec, Roma, California).
Frequently Asked Questions
What is clinical trial NCT06928272 about?
NCT06928272 is a clinical study titled "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study". The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three m...
What is the current status of trial NCT06928272?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2025-09-10. Estimated completion is 2027-12.
What conditions does trial NCT06928272 study?
This clinical trial studies the following conditions: Long COVID.
What interventions are being tested in trial NCT06928272?
The interventions under investigation include: Upadacitinib (DRUG), Pirfenidone (DRUG), Placebo for pirfenidone (DRUG), Placebo for upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06928272?
This trial is sponsored by Douglas D. Fraser, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06928272 being conducted?
This trial has 8 study locations across California, Rio de Janerio, Quebec, Roma, Kampala. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Long COVID
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06928272's enrollment target sits among peer trials
348 10th of 50 higher than 41 of 50 other Long COVID trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Long COVID trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Water-based Activity to Enhance Recovery in Long COVID-19
RECRUITING · NA
-
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
RECRUITING · NA
-
Long-Covid-19 Alleviation Through Learning Mindfulness Study
RECRUITING · NA
-
Sauna for Long Covid
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI